A French trial investigating the results of interrupting Gleevec in metastatic GIST patients has been published (click for abstract). Results indicate imatinib treatment should not be interrupted to avoid reactivation of metastases.
A French trial investigating the results of interrupting Gleevec in metastatic GIST patients has been published (click for abstract). Results indicate imatinib treatment should not be interrupted to avoid reactivation of metastases.